Rathbones Group PLC Decreases Stake in Medtronic PLC $MDT

Posted by George Bondi on May 22nd, 2026

Rathbones Group PLC reduced its stake in shares of Medtronic PLC (NYSE:MDT – Free Report) by 19.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 52,746 shares of the medical technology company’s stock after selling 12,766 shares during the period. Rathbones Group PLC’s holdings in Medtronic were worth $5,067,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Lodestone Wealth Management LLC purchased a new stake in shares of Medtronic during the 4th quarter worth $27,000. Anfield Capital Management LLC boosted its position in shares of Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after buying an additional 230 shares in the last quarter. Valley Wealth Managers Inc. purchased a new stake in shares of Medtronic in the 3rd quarter worth about $29,000. Board of the Pension Protection Fund purchased a new stake in shares of Medtronic in the 4th quarter worth about $29,000. Finally, GoalVest Advisory LLC purchased a new stake in shares of Medtronic in the 4th quarter worth about $29,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Barclays boosted their price objective on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Daiwa Securities Group decreased their price objective on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. UBS Group decreased their price objective on shares of Medtronic from $104.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 22nd. CICC Research assumed coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an “outperform” rating on the stock. Finally, Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and an average target price of $106.45.

Get Our Latest Report on Medtronic

Medtronic Price Performance

NYSE:MDT opened at $78.11 on Friday. The firm has a market cap of $100.29 billion, a price-to-earnings ratio of 21.76, a price-to-earnings-growth ratio of 1.86 and a beta of 0.62. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The company’s 50-day moving average is $83.71 and its two-hundred day moving average is $93.25. Medtronic PLC has a 12-month low of $74.40 and a 12-month high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.38 EPS. Research analysts expect that Medtronic PLC will post 5.56 EPS for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.6%. The ex-dividend date was Friday, March 27th. Medtronic’s dividend payout ratio is 79.11%.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic said the SPR Therapeutics purchase will strengthen its neuromodulation portfolio by adding temporary peripheral nerve stimulation technology for chronic pain, a move that could support longer-term growth and broaden its treatment offerings. PR Newswire article
Positive Sentiment: Reuters reported that the deal expands Medtronic’s portfolio of treatments for chronic pain, reinforcing the company’s strategy to grow in higher-value medical device categories. Reuters article
Neutral Sentiment: Piper Sandler maintained its Hold rating on Medtronic, suggesting analysts are not yet signaling a major re-rating from the news. The Globe and Mail article
Neutral Sentiment: Healthcare stocks were mixed in afternoon trading, so broader sector movement does not appear to be the main driver of Medtronic’s move. Yahoo Finance sector update
Negative Sentiment: Some market commentary framed the SPR deal as a reason for MDT’s stock to slide, likely reflecting concern about acquisition costs and execution risk. Blockonomi article

About Medtronic

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).